May 18, 2015
Akcea Therapeutics has retained The Chase Group to secure a Chief Medical Officer to join the start-up organization. This person will be responsible for the overall strategic direction for development products and programs across all stages of development. These responsibilities will cover the full scope of clinical development functions including pre-clinical activities, Phase I (including human PK/PD) studies, as well as Phase II-IV trial design and execution. This position will work closely with the development teams ensuring effective strategy, design, execution and regulatory submission of development programs.
